All of IsoTis’s outstanding $12.6 million in debt was repaid at closing.
Integra, which focuses on advanced technology in orthobiologics, intends to integrate both IsoTis’s domestic network of independent distributor agents and its global network of independent orthopedics distributors into Integra’s own sales efforts and leverage this expanded distribution.
Switzerland-based IsoTis manufactures, markets and sells a range of bone graft substitutes and other related medical devices that are used to enhance the repair and regeneration of bone in spinal and trauma surgery, total joint replacements and dental applications.
Brian Larkin, president of Integra NeuroSciences, said: “We are excited about the strong sales network that Integra now has for its orthobiologics portfolio. The distribution of IsoTis’s products through the existing network of dealers is critical to the long-term strategy and success of sales of Integra OrthoBiologics.”